A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset

In brief

The aim of this study is to demonstrate the efficacy and to evaluate the safety, pharmacokinetics (PK) and immunogenicity of anakinra in patients with newly diagnosed Still's disease, including SJIA (Systemic juvenile idiopathic arthritis) and AOSD (Adult-onset Still's disease).

Key facts

Study ID

NCT03265132

Run by

Swedish Orphan Biovitrum

People needed

13

Starts

2017-09-26

Expected to finish

2019-05-23

Last updated by the study team

2021-06-30

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent.
• Male and female patients with a body weight ≥ 10 kg.
• Diagnosis of Still's disease.
• If currently on glucocorticoid treatment, a stable dose for at least 1 week prior to randomization.
• If currently on methotrexate treatment, a stable dose for at least 8 weeks prior to randomization.
• Active disease.
• Female patients of childbearing potential must use an effective method of contraception during the study (abstinence being a possible option) as well as present a negative pregnancy test prior to randomization.
• Negative interferon-gamma release assay or Purified protein derivative ( PPD) test within 2 months prior to randomization. If not available, a test should be performed at day of randomization.

You may not qualify if…

• Diagnosis of Still's disease more than 6 months prior to randomization.
• Previous randomization into this study.
• Participation in another concurrent clinical interventional study within 30 days of randomization.
• Treatment with an investigational drug within 5 half-lives prior to randomization.
• Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor.
• Use of the following therapies prior to randomization:
• Narcotic analgesics within 24 hours prior to randomization.
• Dapsone or etanercept within 3 weeks prior to randomization.
• Intraarticular, intramuscular or intravenous administration of glucocorticoids or intravenous immunoglobulin (Ig) within 4 weeks prior to randomization.
• Intravenous Ig with proven Still's disease modifying effect, leflunomide, infliximab or adalimumab within 8 weeks prior to randomization.
• Thalidomide, cyclosporine, mycophenolate mofetil, 6-mercaptopurine, azathioprine, cyclophosphamide, chlorambucil or any other immunosuppressant within 12 weeks prior to randomization.
• Tocilizumab within 12 weeks prior to randomization or any other immunomodulatory medication within 4 half-lives prior to randomization
• Rituximab within 26 weeks prior to randomization.
• Live vaccines within 1 month prior to randomization.
• Known presence or suspicion of active, chronic or recurrent bacterial, fungal or viral infections, including tuberculosis, HIV infection or hepatitis B or C infection.
• Clinical evidence of liver disease or liver injury.
• Presence of severe renal function impairment.
• Presence of neutropenia.
• Presence or suspicion of MAS at baseline.
• A diagnosis of MAS within the last 2 months prior to randomization.
• History of malignancy within 5 years.
• Known hypersensitivity to E coli-derived proteins, or any components of Kineret® (anakinra).
• Pregnant or lactating women.
• Foreseeable inability to cooperate with given instructions or study procedures.
• Presence of any medical or psychological condition or laboratory result that in the opinion of the investigator can interfere with the patient's ability to comply with the protocol requirements or makes the patient not appropriate for inclusion to the study and treatment with IMP.

Where it is running

• University of Alabama Birmingham — Birmingham, Alabama, United States
• Attune Health — Beverly Hills, California, United States
• Rady Children's Hospital & Health Center — San Diego, California, United States
• The Children's Hospital Colorado — Aurora, Colorado, United States
• University of Florida — Gainesville, Florida, United States
• University of Miami — Miami, Florida, United States
• Nicklaus Children's Hospital — Miami, Florida, United States
• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
• Children's Mercy Hospital and Clinics — Kansas City, Kansas, United States
• University of Louisville School of Medicine Research Foundation — Louisville, Kentucky, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Boston Children's Hospital — Boston, Massachusetts, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Saint Paul Rheumatology — Eagan, Minnesota, United States
• University of Minnesota — Minneapolis, Minnesota, United States
• Saint Louis University — St Louis, Missouri, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Institute for Rheumatic and Autoimmune Diseases — Summit, New Jersey, United States
• Hospital for Special Surgery — New York, New York, United States
• Columbia University Medical Center — New York, New York, United States
• UNC Hospitals — Chapel Hill, North Carolina, United States
• Duke Children's Hospital and Health Center — Durham, North Carolina, United States
• Wake Forest Baptist Brenner Medical Center — Winston-Salem, North Carolina, United States
• MetroHealth System — Cleveland, Ohio, United States
• Nationwide Children's Hospital — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.